Golden
Owlstone Medical

Owlstone Medical

Owlstone Medical is a diagnostic medical device company developing non-invasive diagnostics such as breathalyzers for cancer, inflammatory disease and infectious disease.

Owlstone Medical develops non-invasive diagnostics for cancer, inflammatory disease and infectious disease. The company developed a breathalyzer for disease detection. Their Breath Biopsy platform is used to discover novel non-invasive biomarkers in breath which could transition to point-of-care. The ReCIVA Breath Sampler collects breath samples and analyzes volatile organic compounds (VOCs) using the microchip chemical senor technology, FAIMS (High Field Asymmetric waveform Ion Mobility Spectrometry), which detects biomarkers of disease. 



Owlstone is developing tests for lung cancer, colorectal cancer and asthma stratification by therapeutic response. The company also offers Breath Biopsy products and services to academic, clinical and pharma partners looking to develop breath based diagnostics for their own applications. 



Timeline

November 8, 2019

Thermo Fisher, Owlstone Medical collaborate for cancer diagnosis

Funding rounds

2 Results
Funding round
Funding round
Funding round amount (USD)
Funding round amount (USD)
Funding type
Funding type
Funding round date
Funding round date
Investment
Investment

People

Name
Role
LinkedIn

Billy Boyle

Co-Founder, CEO



David Ruiz-Alonso

Co-Founder, COO



Martin Cartwright

CFO



Max Allsworth

CSO



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References